"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Quelicin Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Quelicin (succinylcholine chloride) Injection is a short-acting depolarizing skeletal muscle relaxant used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. This medication is available in generic form. Common side effects include cardiac arrest, malignant hyperthermia, arrhythmias, slow or rapid heart rate, high or low blood pressure, high levels of potassium in the blood, prolonged respiratory depression or apnea, increased intraocular pressure, muscle twitching, jaw rigidity, postoperative muscle pain, acute renal failure, excessive salivation, and rash.
The dosage of Quelicin is individualized and should always be determined by the physician after careful assessment of the patient. Quelicin may interact with promazine, oxytocin, aprotinin, antibiotics, quinidine, p-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, diethylether, isoflurane, desflurane, metoclopramide, terbutaline, oral contraceptives, glucocorticoids, or monoamine oxidase inhibitors. Tell your doctor all medications and supplements you use. During pregnancy, Quelicin should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Quelicin (succinylcholine chloride) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Quelicin FDA Prescribing Information: Side Effects
Adverse reactions to succinylcholine consist primarily of an extension of its pharmacological actions. Succinylcholine causes profound muscle relaxation resulting in respiratory depression to the point of apnea; this effect may be prolonged. Hypersensitivity reactions, including anaphylaxis, may occur in rare instances. The following additional adverse reactions have been reported: cardiac arrest, malignant hyperthermia, arrhythmias, bradycardia, tachycardia, hypertension, hypotension, hyperkalemia, prolonged respiratory depression or apnea, increased intraocular pressure, muscle fasciculation, jaw rigidity, postoperative muscle pain, rhabdomyolysis with possible myoglobinuric acute renal failure, excessive salivation, and rash.
There have been post-marketing reports of severe allergic reactions (anaphylactic and anaphylactoid reactions) associated with use of neuromuscular blocking agents, including succinylcholine. These reactions, in some cases, have been life threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (See WARNINGS and PRECAUTIONS).
Read the entire FDA prescribing information for Quelicin (Succinylcholine Chloride Injection) »
Additional Quelicin Information
Report Problems to the Food and Drug Administration
Find out what women really need.